388 related articles for article (PubMed ID: 17064299)
1. Histopathological features of breast cancer in carriers of ATM gene variants.
Balleine RL; Murali R; Bilous AM; Farshid G; Waring P; Provan P; Byth K; Thorne H; ; Kirk JA
Histopathology; 2006 Nov; 49(5):523-32. PubMed ID: 17064299
[TBL] [Abstract][Full Text] [Related]
2. Frequency of the ATM IVS10-6T-->G variant in Australian multiple-case breast cancer families.
Lindeman GJ; Hiew M; Visvader JE; Leary J; Field M; Gaff CL; Gardner RJ; Trainor K; Cheetham G; Suthers G; Kirk J
Breast Cancer Res; 2004; 6(4):R401-7. PubMed ID: 15217508
[TBL] [Abstract][Full Text] [Related]
3. ATM germline mutations in Spanish early-onset breast cancer patients negative for BRCA1/BRCA2 mutations.
Brunet J; Gutiérrez-Enríquez S; Torres A; Bérez V; Sanjosé S; Galceran J; Izquierdo A; Menéndez JA; Gumà J; Borràs J
Clin Genet; 2008 May; 73(5):465-73. PubMed ID: 18384426
[TBL] [Abstract][Full Text] [Related]
4. Two ATM variants and breast cancer risk.
Thompson D; Antoniou AC; Jenkins M; Marsh A; Chen X; Wayne T; Tesoriero A; Milne R; Spurdle A; Thorstenson Y; Southey M; Giles GG; Khanna KK; Sambrook J; Oefner P; Goldgar D; Hopper JL; Easton D; Chenevix-Trench G;
Hum Mutat; 2005 Jun; 25(6):594-5. PubMed ID: 15880680
[TBL] [Abstract][Full Text] [Related]
5. ATM germline mutations in women with familial breast cancer and a relative with haematological malignancy.
Paglia LL; Laugé A; Weber J; Champ J; Cavaciuti E; Russo A; Viovy JL; Stoppa-Lyonnet D
Breast Cancer Res Treat; 2010 Jan; 119(2):443-52. PubMed ID: 19404735
[TBL] [Abstract][Full Text] [Related]
6. Contribution of mutations in ATM to breast cancer development in the Czech population.
Soukupova J; Dundr P; Kleibl Z; Pohlreich P
Oncol Rep; 2008 Jun; 19(6):1505-10. PubMed ID: 18497957
[TBL] [Abstract][Full Text] [Related]
7. Molecular profile of ductal carcinoma in situ of the breast in BRCA1 and BRCA2 germline mutation carriers.
van der Groep P; van Diest PJ; Menko FH; Bart J; de Vries EG; van der Wall E
J Clin Pathol; 2009 Oct; 62(10):926-30. PubMed ID: 19541683
[TBL] [Abstract][Full Text] [Related]
8. Germline ATM mutational analysis in BRCA1/BRCA2 negative hereditary breast cancer families by MALDI-TOF mass spectrometry.
Graña B; Fachal L; Darder E; Balmaña J; Ramón Y Cajal T; Blanco I; Torres A; Lázaro C; Diez O; Alonso C; Santamariña M; Velasco A; Teulé A; Lasa A; Blanco A; Izquierdo A; Borràs J; Gutiérrez-Enríquez S; Vega A; Brunet J
Breast Cancer Res Treat; 2011 Jul; 128(2):573-9. PubMed ID: 21445571
[TBL] [Abstract][Full Text] [Related]
9. The DNA damage signalling kinase ATM is aberrantly reduced or lost in BRCA1/BRCA2-deficient and ER/PR/ERBB2-triple-negative breast cancer.
Tommiska J; Bartkova J; Heinonen M; Hautala L; Kilpivaara O; Eerola H; Aittomäki K; Hofstetter B; Lukas J; von Smitten K; Blomqvist C; Ristimäki A; Heikkilä P; Bartek J; Nevanlinna H
Oncogene; 2008 Apr; 27(17):2501-6. PubMed ID: 17982490
[TBL] [Abstract][Full Text] [Related]
10. Promoter methylation patterns of ATM, ATR, BRCA1, BRCA2 and p53 as putative cancer risk modifiers in Jewish BRCA1/BRCA2 mutation carriers.
Kontorovich T; Cohen Y; Nir U; Friedman E
Breast Cancer Res Treat; 2009 Jul; 116(1):195-200. PubMed ID: 18642075
[TBL] [Abstract][Full Text] [Related]
11. ATM allelic variants associated to hereditary breast cancer in 94 Chilean women: susceptibility or ethnic influences?
Tapia T; Sanchez A; Vallejos M; Alvarez C; Moraga M; Smalley S; Camus M; Alvarez M; Carvallo P
Breast Cancer Res Treat; 2008 Jan; 107(2):281-8. PubMed ID: 17351744
[TBL] [Abstract][Full Text] [Related]
12. Phenotypic analysis of familial breast cancer: comparison of BRCAx tumors with BRCA1-, BRCA2-carriers and non-familial breast cancer.
Aloraifi F; Alshehhi M; McDevitt T; Cody N; Meany M; O'Doherty A; Quinn CM; Green AJ; Bracken A; Geraghty JG
Eur J Surg Oncol; 2015 May; 41(5):641-6. PubMed ID: 25736863
[TBL] [Abstract][Full Text] [Related]
13. Hereditary breast cancer: from molecular pathology to tailored therapies.
Tan DS; Marchiò C; Reis-Filho JS
J Clin Pathol; 2008 Oct; 61(10):1073-82. PubMed ID: 18682420
[TBL] [Abstract][Full Text] [Related]
14. IVS10-6T>G, an ancient ATM germline mutation linked with breast cancer.
Broeks A; Urbanus JH; de Knijff P; Devilee P; Nicke M; Klöpper K; Dörk T; Floore AN; van't Veer LJ
Hum Mutat; 2003 May; 21(5):521-8. PubMed ID: 12673794
[TBL] [Abstract][Full Text] [Related]
15. ATM variants and cancer risk in breast cancer patients from Southern Finland.
Tommiska J; Jansen L; Kilpivaara O; Edvardsen H; Kristensen V; Tamminen A; Aittomäki K; Blomqvist C; Børresen-Dale AL; Nevanlinna H
BMC Cancer; 2006 Aug; 6():209. PubMed ID: 16914028
[TBL] [Abstract][Full Text] [Related]
16. Spectrum of ATM gene mutations in a hospital-based series of unselected breast cancer patients.
Dörk T; Bendix R; Bremer M; Rades D; Klöpper K; Nicke M; Skawran B; Hector A; Yamini P; Steinmann D; Weise S; Stuhrmann M; Karstens JH
Cancer Res; 2001 Oct; 61(20):7608-15. PubMed ID: 11606401
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the role of Finnish ataxia-telangiectasia mutations in hereditary predisposition to breast cancer.
Pylkäs K; Tommiska J; Syrjäkoski K; Kere J; Gatei M; Waddell N; Allinen M; Karppinen SM; Rapakko K; Kääriäinen H; Aittomäki K; Blomqvist C; Mustonen A; Holli K; Khanna KK; Kallioniemi OP; Nevanlinna H; Winqvist R
Carcinogenesis; 2007 May; 28(5):1040-5. PubMed ID: 17166884
[TBL] [Abstract][Full Text] [Related]
18. Contributions of ATM mutations to familial breast and ovarian cancer.
Thorstenson YR; Roxas A; Kroiss R; Jenkins MA; Yu KM; Bachrich T; Muhr D; Wayne TL; Chu G; Davis RW; Wagner TM; Oefner PJ
Cancer Res; 2003 Jun; 63(12):3325-33. PubMed ID: 12810666
[TBL] [Abstract][Full Text] [Related]
19. Lack of association between ATM C.1066-6T > G mutation and breast cancer risk: a meta-analysis of 8,831 cases and 4,957 controls.
Ding H; Mao C; Li SM; Liu Q; Lin L; Chen Q
Breast Cancer Res Treat; 2011 Jan; 125(2):473-7. PubMed ID: 20544271
[TBL] [Abstract][Full Text] [Related]
20. Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Breast Cancer Linkage Consortium.
Lancet; 1997 May; 349(9064):1505-10. PubMed ID: 9167459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
